反应详情

Following the procedure for the preparation of 2-{4-[4-Pyridin4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymethyl}-quinoxaline but substituting 4-(1-Methyl4-pyridin4-yl-1H-pyrazol-3-yl)-phenol and (8-Methoxy-quinolin-2-yl)-methanol provided the title compound. 1H NMR (400 MHz, CDCl3) δ 8.45 (d, J=6.2 Hz, 2 H), 8.15 (d, J=8.7 Hz, 1H), 7.73 (d, J=8.3 Hz,1H), 7.55 (s, 1H), 7.44 (m, 1 H), 7.37 (m, 3 H), 7.15 (d, J=5.8, Hz, 2 H), 7.07 (d, J=7.5 Hz, 1H), 6.99 (d, J=8.7 Hz, 2 H), 5.46 (s, 2H), 4.08 (s, 3 H), 3.94 (s, 3H); MS: (M+H m/z=423.1).